User login
Image by Matthias Zepper
Researchers have reportedly identified precursor cells that can be matured into transplantable hematopoietic stem/progenitor cells (HSPCs) in the lab.
The investigators discovered the precursor cells in the placentas and embryos of mice, but the team believes their findings could aid the development of patient-specific HSPCs and more differentiated blood products for cell-replacement therapy in humans.
“To cure disease in the long-term, we need to be able to transplant something that can keep producing new blood cells and won’t be rejected by the patient’s body,” said study author Kateri Moore, DVM, of the Icahn School of Medicine at Mount Sinai in New York, New York.
“We are excited by the results of our study. The precursor cells can be matured in the lab to transplantable HSPCs. Our reprogramming process can inform developmental hematopoiesis and vice-versa.”
Dr Moore and her colleagues described this work in Developmental Cell.
With previous work, the researchers reprogrammed mouse fibroblasts to become HSPCs. They showed that this process occurred through hemogenic precursors that are Prom1+Sca1+CD34+CD45− (PS34CD45−).
So for the current study, the investigators examined mouse placentas and embryos, looking for cells with the same phenotype. They were able to find and analyze PS34CD45− cells.
Investigation revealed that PS34CD45− cells express endothelial and hematopoietic markers. And the cells originate in embryonic tissue and localize to the vascular labyrinth.
Furthermore, the researchers said global gene expression profiles of PS34CD45− cells correlate with reprogrammed precursors and establish a hemogenic precursor cell molecular signature.
In culture, PS34CD45− cells gave rise to multi-lineage hematopoietic colonies. PS34CD45− cells generated B and T lymphocytes and engrafted in primary and secondary immunodeficient mice.
The investigators said the next step is to test these findings in humans.
“Our ultimate goal is to grow blood-forming cells in the lab and improve efficiencies to generate patient-specific blood cells,” Dr Moore said. “This study brings us a step closer to reaching this goal.” 
Image by Matthias Zepper
Researchers have reportedly identified precursor cells that can be matured into transplantable hematopoietic stem/progenitor cells (HSPCs) in the lab.
The investigators discovered the precursor cells in the placentas and embryos of mice, but the team believes their findings could aid the development of patient-specific HSPCs and more differentiated blood products for cell-replacement therapy in humans.
“To cure disease in the long-term, we need to be able to transplant something that can keep producing new blood cells and won’t be rejected by the patient’s body,” said study author Kateri Moore, DVM, of the Icahn School of Medicine at Mount Sinai in New York, New York.
“We are excited by the results of our study. The precursor cells can be matured in the lab to transplantable HSPCs. Our reprogramming process can inform developmental hematopoiesis and vice-versa.”
Dr Moore and her colleagues described this work in Developmental Cell.
With previous work, the researchers reprogrammed mouse fibroblasts to become HSPCs. They showed that this process occurred through hemogenic precursors that are Prom1+Sca1+CD34+CD45− (PS34CD45−).
So for the current study, the investigators examined mouse placentas and embryos, looking for cells with the same phenotype. They were able to find and analyze PS34CD45− cells.
Investigation revealed that PS34CD45− cells express endothelial and hematopoietic markers. And the cells originate in embryonic tissue and localize to the vascular labyrinth.
Furthermore, the researchers said global gene expression profiles of PS34CD45− cells correlate with reprogrammed precursors and establish a hemogenic precursor cell molecular signature.
In culture, PS34CD45− cells gave rise to multi-lineage hematopoietic colonies. PS34CD45− cells generated B and T lymphocytes and engrafted in primary and secondary immunodeficient mice.
The investigators said the next step is to test these findings in humans.
“Our ultimate goal is to grow blood-forming cells in the lab and improve efficiencies to generate patient-specific blood cells,” Dr Moore said. “This study brings us a step closer to reaching this goal.”
Image by Matthias Zepper
Researchers have reportedly identified precursor cells that can be matured into transplantable hematopoietic stem/progenitor cells (HSPCs) in the lab.
The investigators discovered the precursor cells in the placentas and embryos of mice, but the team believes their findings could aid the development of patient-specific HSPCs and more differentiated blood products for cell-replacement therapy in humans.
“To cure disease in the long-term, we need to be able to transplant something that can keep producing new blood cells and won’t be rejected by the patient’s body,” said study author Kateri Moore, DVM, of the Icahn School of Medicine at Mount Sinai in New York, New York.
“We are excited by the results of our study. The precursor cells can be matured in the lab to transplantable HSPCs. Our reprogramming process can inform developmental hematopoiesis and vice-versa.”
Dr Moore and her colleagues described this work in Developmental Cell.
With previous work, the researchers reprogrammed mouse fibroblasts to become HSPCs. They showed that this process occurred through hemogenic precursors that are Prom1+Sca1+CD34+CD45− (PS34CD45−).
So for the current study, the investigators examined mouse placentas and embryos, looking for cells with the same phenotype. They were able to find and analyze PS34CD45− cells.
Investigation revealed that PS34CD45− cells express endothelial and hematopoietic markers. And the cells originate in embryonic tissue and localize to the vascular labyrinth.
Furthermore, the researchers said global gene expression profiles of PS34CD45− cells correlate with reprogrammed precursors and establish a hemogenic precursor cell molecular signature.
In culture, PS34CD45− cells gave rise to multi-lineage hematopoietic colonies. PS34CD45− cells generated B and T lymphocytes and engrafted in primary and secondary immunodeficient mice.
The investigators said the next step is to test these findings in humans.
“Our ultimate goal is to grow blood-forming cells in the lab and improve efficiencies to generate patient-specific blood cells,” Dr Moore said. “This study brings us a step closer to reaching this goal.”